What cardiac diagnosis should be considered in a patient with a decreased left ventricular ejection fraction?

Cardiac Diagnosis with Decreased Ejection Fraction

A decreased left ventricular ejection fraction (LVEF ≤40%) defines heart failure with reduced ejection fraction (HFrEF), which is the primary cardiac diagnosis to consider and requires immediate initiation of guideline-directed medical therapy to reduce mortality and hospitalization 1, 2.

Diagnostic Classification

When you encounter a patient with decreased ejection fraction, classify them according to the following framework 2:

• HFrEF: LVEF ≤40%
• HFmrEF (mildly reduced): LVEF 41-49%
• HFpEF (preserved): LVEF ≥50%

The diagnosis of HFrEF requires three components 1, 3:

1. Clinical symptoms: Dyspnea, orthopnea, peripheral edema, exertional limitation
2. Elevated natriuretic peptides: BNP or NT-proBNP above age-specific thresholds
3. Imaging confirmation: Transthoracic echocardiography (TTE) demonstrating LVEF ≤40% with or without left ventricular dilation

Underlying Etiologies to Identify

Ischemic cardiomyopathy is the most common cause of HFrEF and must be actively excluded or confirmed, as it affects device therapy decisions 1, 4, 5. Other etiologies include:

• Dilated cardiomyopathy (DCM)
• Hypertensive heart disease
• Valvular heart disease
• Myocarditis
• Cardiotoxic drug exposure
• Genetic/familial cardiomyopathy

Immediate Management Algorithm

The "Fantastic Four" foundational therapies must be initiated rapidly—within days to weeks, not months—to improve mortality and quality of life 1, 3, 6:

First-Line Therapy (Class I Recommendations)

1. ACE inhibitor OR Angiotensin Receptor-Neprilysin Inhibitor (ARNI)

   • ARNI (sacubitril/valsartan) is superior to ACE inhibitors and should replace ACE-I in symptomatic patients already on ACE-I therapy 1
   • Start low, uptitrate to target doses proven in trials
   • Monitor renal function and potassium

2. Beta-blocker (bisoprolol, carvedilol, or metoprolol succinate only)

   • Must use one of these three evidence-based agents 1, 7
   • Initiate alongside RAAS inhibition, not sequentially
   • Uptitrate to maximum tolerated dose

3. Mineralocorticoid Receptor Antagonist (MRA)

   • Add spironolactone or eplerenone if symptoms persist despite ACE-I/ARNI and beta-blocker 1, 7
   • Requires close monitoring of potassium and renal function

4. SGLT2 Inhibitor

   • Reduces cardiovascular and all-cause mortality regardless of diabetes status 3, 5
   • Should be initiated early in all HFrEF patients unless contraindicated

Symptomatic Relief

Diuretics are mandatory for congestion management but do not reduce mortality 1, 8. Use loop diuretics (furosemide, bumetanide, torsemide) titrated to relieve symptoms and achieve euvolemia.

Device Therapy Considerations

ICD for Primary Prevention

An ICD is indicated to reduce sudden cardiac death and all-cause mortality in patients with 1, 9:

• LVEF ≤35% despite ≥3 months of optimal medical therapy
• NYHA Class II-III symptoms
• Expected survival >1 year with good functional status
• Ischemic etiology (unless MI within prior 40 days)
• Non-ischemic DCM (Class I, Level B)

Critical caveat: ICD implantation within 40 days of MI does not improve prognosis and is contraindicated 1.

Cardiac Resynchronization Therapy (CRT)

CRT reduces mortality and hospitalization in patients with 1, 7, 9:

• LVEF ≤35%
• NYHA Class III-IV (or ambulatory Class IV if transplant listed)
• Sinus rhythm
• QRS ≥150 ms (Class I, Level A)
• QRS 120-149 ms with LBBB morphology (Class I, Level B)

Patients with QRS 120-149 ms without LBBB have weaker evidence (Class IIa-IIb) 7, 9.

Common Pitfalls to Avoid

1. Do not use diltiazem or verapamil—they worsen HF and increase hospitalizations 1

2. Do not combine ACE-I + ARB + MRA—this triple combination increases hyperkalemia and renal dysfunction risk 1

3. Do not delay uptitration—rapid implementation of all four foundational therapies within 6 months substantially improves prognosis 4, 5

4. Do not switch to ARB for minor ACE-I side effects—ACE inhibitors have stronger evidence; only switch if adverse effects are intolerable 7

5. Do not implant ICD in NYHA Class IV patients with refractory symptoms unless they are candidates for CRT, ventricular assist device, or heart transplantation 10, 9

Additional Therapies for Specific Populations

• Ivabradine: If heart rate >70 bpm despite beta-blocker, in sinus rhythm 5
• Hydralazine/isosorbide dinitrate: Particularly beneficial in self-identified African Americans 8
• Vericiguat: For high-risk patients with recent HF hospitalization 5
• Intravenous iron: If iron deficiency present, improves exercise capacity and reduces hospitalizations 6

Prognosis Context

Despite optimal therapy, HFrEF carries a 5-year survival rate of only 25% after hospitalization 5. This underscores the critical importance of early diagnosis, aggressive medical optimization, and appropriate device therapy selection to maximize both survival and quality of life.